Tarsus Pharmaceuticals (TARS) Operating Expenses (2019 - 2026)

Tarsus Pharmaceuticals' Operating Expenses history runs 8 years deep, the most recent figure standing at $168.2 million for Q1 2026.

• On a quarterly basis, Operating Expenses rose 60.76% year-over-year to $168.2 million in Q1 2026; TTM through Mar 2026 was $585.9 million, a 70.89% increase from a year earlier, with the FY2025 full-year figure at $522.3 million, up 72.09% from the prior year.
• Operating Expenses grew to $168.2 million in Q1 2026 per TARS's latest filing, from $159.6 million in the prior quarter.
• Across five years, Operating Expenses topped out at $168.2 million in Q1 2026 and bottomed at $20.1 million in Q1 2022.
• The 5-year median for Operating Expenses is $65.3 million (2024), against an average of $73.1 million.
• Across the five-year window, Operating Expenses fell 11.7% in 2022 and soared 137.86% in 2024, its largest moves.
• Year by year, Operating Expenses stood at $25.1 million in 2022, then soared by 129.54% to $57.5 million in 2023, then soared by 57.89% to $90.8 million in 2024, then jumped by 75.76% to $159.6 million in 2025, then grew by 5.34% to $168.2 million in 2026.
• Per Business Quant, the three latest TARS Operating Expenses figures stand at $168.2 million (Q1 2026), $159.6 million (Q4 2025), and $133.2 million (Q3 2025).